Selected article for: "major determinant and MERS cov"

Author: Wang, Ying-Ting; Landeras-Bueno, Sara; Hsieh, Li-En; Terada, Yutaka; Kim, Kenneth; Ley, Klaus; Shresta, Sujan; Saphire, Erica Ollmann; Regla-Nava, Jose Angel
Title: Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV-2
  • Cord-id: tcc7e6ls
  • Document date: 2020_5_20
  • ID: tcc7e6ls
    Snippet: SUMMARY SARS-Coronavirus-2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), an infectious respiratory disease causing thousands of deaths and overwhelming public health systems. The international spread of SARS-CoV-2 is associated with the ease of global travel, and societal dynamics, immunologic naiveté of the host population, and muted innate immune responses. Based on these factors and the expanding geographic scale of the disease, the WHO declared the COVID-19 outbreak a pandemic–
    Document: SUMMARY SARS-Coronavirus-2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), an infectious respiratory disease causing thousands of deaths and overwhelming public health systems. The international spread of SARS-CoV-2 is associated with the ease of global travel, and societal dynamics, immunologic naiveté of the host population, and muted innate immune responses. Based on these factors and the expanding geographic scale of the disease, the WHO declared the COVID-19 outbreak a pandemic–the first caused by a coronavirus. In this review, we summarize the current epidemiological status of COVID-19 and consider the virological and immunological lessons, animal models, and tools developed in response to prior SARS-CoV and MERS-CoV outbreaks that can serve as resources for development of SARS-CoV-2 therapeutics and vaccines. In particular, we discuss structural insights into the SARS-CoV-2 spike protein, a major determinant of transmissibility, and discuss key molecular aspects that will aid in understanding and fighting this new global threat.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and lung tissue: 1, 2
    • adaptive immunity and adjuvant antigen: 1, 2
    • adaptive immunity and administration route: 1, 2
    • adaptive immunity and low morbidity: 1
    • adaptive immunity and lung immune response: 1
    • adaptive immunity and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • additional validation and long amino acid: 1